Lyon, 26 February 2009 /b3c newswire / - BioSquare, the international business convention, will bring key players from the pharmaceutical and biotechnology industries together in Lyon from 9 - 11 March. The ninth BioSquare convention will be held at the Lyon Congress Center, providing the ideal opportunity to analyze and discuss trends and developments in the sector.
One-to-one meetings, workshops, panels… hundreds of opportunities
Above all, BioSquare provides the opportunity to meet a broad cross-section of fellow biotechnology professionals by means of one-to-one business meetings and company presentations.
Once again, in 2009 business leaders and executives from biotechnology firms, professors, eminent members of business networks, and professionals from innovative industries will meet together and develop scientific, industrial and financial exchanges around new breakthroughs and developments in their sector.
Thanks to BioPartnering.com, these meetings can be set up prior to the start of the convention. This software, a comprehensive database of stakeholders in the European and North American biotechnology sector, has been used at major industry events the world over including in London, California and Vancouver. Developed to meet the specific requirements of biotechnology companies, this tool is available to participants from the moment they register. It allows them to enter in direct contact with other participants corresponding to their areas of interest and expectations. This makes it possible to optimize the time spent at the BioSquare convention.
The experts discuss and debate
As an extension to the individual meetings and in order to widen the debate, six workshops and two panels will be organized during BioSquare 2009. Experienced participants will analyze the changes and trends in the sector and the strategies to adopt in order to meet the technological, economic and financial challenges facing biotechnology industries today. In line with the attitudes of the contributing speakers and moderators, all professionals involved in the day-to-day activities of the biotechnologies industry, these debates aim to be useful, constructive and solutions-focused.
These eight events include:
* The Brain Device Interface – Monday 9 March, 16:00 – 17:30
This panel aims to map out the medium-term opportunities and issues concerning the three ways in which the brain / device interaction can be used in human health services and treatment:
- By direct contact, with matter exchange, in the field of drug delivery.
- By direct contact with information or energy exchange, with applications in the treatment of neurodegenerative diseases or in implants to treat sight impairments.
- By indirect contact, with information or energy exchange, with an application in magnetoencephalography (MEG) brain activity imaging, for example.
The participants in this session will present the latest innovations in brain / device interfaces and will discuss the economic opportunities they present.
Pr Alim Louis Benabid, Professor Emeritus, University Joseph Fourier, Grenoble.
Fernand Badano, President, Valtronic Technologies
Jonas Garding, R&D Director, Elekta
Paolo Mangiagalli, Ph.D, Advanced Technology R&D Manager ,BD Medical.
Gilles Rubinstenn, Chief Executive Officer, Fondation Pierre Gilles de Genne
* More R&D investment but no more drugs approved: what’s wrong? Monday 9 March, 14:15 – 15:30
This panel will look at the major issues in the pharmaceutical industry today. Research and development budgets are constantly being increased but the number of drugs marketed remains limited. Are the instruments for validation at fault? Are the regulatory authorities too stringent? Have the recent examples of drugs withdrawn from sale following the reporting of adverse effects hindered development?
Richard Seebrook, Development Director, Wellcome Trust
Ludo Lauwers, Vice-President, Janssen Pharmaceutica NV
Daniel Cohen, Cheif Executive Officer, Pharnext
Jean-Michel Alexandre, Former Director, EMEA
Mondher Toumi, President – Founder, Creativ Ceutical
Philippe Pouletty, Director of France Biotech, Founder of Truffle Capital
* The cleantech market in Europe – Monday 9 March, 10:45 – 12:00
Cleantechs and biotechs are based on the same technology and use identical tools. Could this common ground lead to synergy or, conversely, competition in obtaining funding for example? The speakers at this workshop will debate on the positioning of these two markets and how to make the most of this synergy.
François Houssin, Development Manager, European Listing, NYSE Euronext
Peter Rosholm, Vice-President, Novozymes
Dr Richard J. LaDuca, Development Director, Genencor
Albin Jourda, Managing director, Gallium Moore
For the full program of panels and workshops: http://www.biosquare.com/files/biosquare-2009-program.pdf
Consult the list of speakers to date: http://www.biosquare.com/speakers.html
Lyon, the Life Sciences capital
From 9 – 11 March 2009 Lyon will be the undisputed capital of the Life Sciences world as it will host both the BioSquare international biotechnologies business convention and BioVision, the World Life Sciences Forum. Holding these events simultaneously offers participants the opportunity to understand the stakes and the concrete applications of Life Sciences. Three thousand participants from the world over are expected to attend BioVision which will tackle the major theme of the role of Life Sciences in meeting the challenges of urban expansion and devote time to the latest breakthroughs in the Life Sciences field.
RESOURCES AND CONTACTS
Next press release: program and speakers – accreditation 2 March 2009
For more information on BioSquare, see the website: www.biosquare.com
Don't forget to register. : Registration is free for members of the press.
Virginie Palpacuer - Kaelia - Tel: +33 (0)4 72 00 35 36 –
Juliette Bastin - Kaelia - Tel: +33 (0)4 72 00 46 86 -
Nathalie Cayuela - Kaelia - Tel: +33 (0)4 72 00 35 85 -